These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 16868082)

  • 21. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
    Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
    Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrasound for drug and gene delivery to the brain.
    Hynynen K
    Adv Drug Deliv Rev; 2008 Jun; 60(10):1209-17. PubMed ID: 18486271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Rationale for Herceptin in the clinical use].
    Ebi H; Sasaki Y
    Nihon Rinsho; 2002 Mar; 60(3):463-7. PubMed ID: 11904959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
    Suter TM; Cook-Bruns N; Barton C
    Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biodegradable nanoparticles for targeted ultrasound imaging of breast cancer cells in vitro.
    Liu J; Li J; Rosol TJ; Pan X; Voorhees JL
    Phys Med Biol; 2007 Aug; 52(16):4739-47. PubMed ID: 17671332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MR-guided focused ultrasound for brain ablation and blood-brain barrier disruption.
    Huang Y; Hynynen K
    Methods Mol Biol; 2011; 711():579-93. PubMed ID: 21279624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles.
    Lee AL; Wang Y; Cheng HY; Pervaiz S; Yang YY
    Biomaterials; 2009 Feb; 30(5):919-27. PubMed ID: 19042015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
    Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
    Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].
    Beuzeboc P; Scholl S; Garau XS; Vincent-Salomon A; Cremoux PD; Couturier J; Palangié T; Pouillart P
    Bull Cancer; 1999 Jun; 86(6):544-9. PubMed ID: 10417428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
    Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
    Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macromolecular delivery across the blood-brain barrier.
    Hynynen K
    Methods Mol Biol; 2009; 480():175-85. PubMed ID: 19085123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
    Hortobagyi GN
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
    Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
    Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
    Stemmler HJ; Schmitt M; Willems A; Bernhard H; Harbeck N; Heinemann V
    Anticancer Drugs; 2007 Jan; 18(1):23-8. PubMed ID: 17159499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
    Chang HR
    Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
    Garnock-Jones KP; Keating GM; Scott LJ
    BioDrugs; 2010 Jun; 24(3):207-9. PubMed ID: 20462285
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.